20:01 , May 9, 2018 |  BC Innovations  |  Distillery Therapeutics

Renal; cardiovascular; hepatic

INDICATION: Renal failure; heart failure; liver failure Mouse studies suggest inhibiting YY1 or its co-repressor FKBP12 could help treat chronic renal, heart and liver failure. In a mouse model of urethral obstruction-induced chronic renal failure,...
16:04 , Mar 26, 2018 |  BC Extra  |  Preclinical News

Bradner, Gray explore targeted degradation-based model systems

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray published a paper in Nature Chemical Biology demonstrating a generalizable target-specific protein degradation system that can be used to create preclinical models that offer better control...
16:01 , Mar 26, 2018 |  BC Innovations  |  Translation in Brief

Tagging out

C4 Therapeutics Inc. co-founders James Bradner and Nathanael Gray have demonstrated in a paper published in Nature Chemical Biology that targeted protein degradation can be used to create preclinical models that offer better control over...
00:16 , Apr 7, 2017 |  BC Innovations  |  Targets & Mechanisms

Mastering mTOR

The master regulator mTOR has made its mark as the target of dozens of drugs and clinical candidates for diseases ranging from cancer to diabetes, but David Sabatini thinks its full therapeutic value won’t be...
00:51 , Mar 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Mouse studies suggest topical tacrolimus could help treat lymphedema. In a mouse tail model of lymphedema, a topical formulation of tacrolimus decreased tail swelling and volume, soft tissue thickness, infiltration of inflammatory cells...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
08:00 , Jan 28, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: Small molecule-activated chimeric antigen receptor (CAR) T cells

Drug platforms TECHNOLOGY: Cell therapy A small molecule-regulated on-switch incorporated into therapeutic CAR T cells could help regulate the cells' activity. The designed switch contained rapamycin-binding domains derived from FK506 binding protein 1A 12kDa (...
08:00 , Jan 18, 2016 |  BioCentury  |  Strategy

Warp's independence day

Stephen Hansen, Associate Editor   New revelations about the breadth of Warp Drive Bio LLC's platform, coupled with the lengthy biotech boom, led the company and partner Sanofi to toss out their 2012 build-to-buy deal...
07:00 , Mar 24, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer CD40; FK506 binding protein 1A 12 kDa (FKBP1A); myeloid differentiation primary response gene 88 (MYD88) A study in mice suggests...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Fibroblast growth factor-2 (FGF-2)-secreting osteoblasts could help promote bone repair by stem cells Mouse studies suggest that FGF-2-secreting osteoblasts could help promote bone repair by...